Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-media...
Enregistré dans:
Auteurs principaux: | Machado Á, Torres T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e61 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
par: Yuliya Lytvyn, PhD, et autres
Publié: (2022) -
Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
par: Annunziata Dattola, et autres
Publié: (2021) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
par: Riccardo G. Borroni, et autres
Publié: (2021) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
par: Beck KM, et autres
Publié: (2018) -
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
par: Reddy V, et autres
Publié: (2020)